Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · MAXCYTE, INC. (MXCT)

MaxCyte to buy Akron Bio for $151.8 million in cash and stock

Mixed Impact 5 of 5 m&a

MaxCyte agreed to acquire Akron BioProducts for total consideration of $151.8 million, including $105.0 million in cash at closing, 20,639,733 new common shares, and $20.0 million in deferred cash payments, with closing expected before the end of 2026. The same day it reported third quarter revenue up 49% and a narrower net loss, and raised full-year 2026 revenue guidance to at least $34.5 million, but the deal adds share dilution, a new credit facility and reduced expected year-end cash.

Key points

  • Q3 2026 total revenue was $10.2 million, up 49% from $6.8 million; net loss narrowed to $4.8 million from $12.4 million
  • Full-year 2026 total revenue guidance raised to at least $34.5 million, excluding the Akron acquisition
  • Akron terms: $105.0 million cash at closing, 20,639,733 shares, and $20.0 million deferred in two $10.0 million payments in 2028 and 2029
  • Funding includes a MidCap Financial facility of up to $75.0 million; closing is subject to HSR review and Nasdaq listing approval

The filing

CompanyMAXCYTE, INC. (MXCT)
Form8-K, current report
Filed with the SECNov 10, 2026, 8:21 AM ET
Accession number0001104659-26-124829

Items reported: 1.01 Material Definitive Agreement2.02 Results of Operations3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 8:40 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.